Basilea Pharmaceutica AG
BPMUF
$54.00
$1.172.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 75.71% | 77.95% | -9.52% | -3.67% | 6.64% |
| Total Other Revenue | 263.80% | 268.42% | -31.85% | -27.44% | -83.09% |
| Total Revenue | 83.35% | 85.68% | -10.68% | -4.90% | -12.27% |
| Cost of Revenue | -11.67% | -10.55% | 63.39% | 73.96% | 71.67% |
| Gross Profit | 15,231.59% | 15,427.28% | -54.29% | -51.33% | -101.13% |
| SG&A Expenses | 1.08% | 2.36% | -1.24% | 5.15% | 22.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.40% | -8.24% | 42.38% | 51.59% | 60.06% |
| Operating Income | 421.32% | 425.40% | -75.29% | -73.69% | -160.12% |
| Income Before Tax | 349.34% | 352.52% | -77.15% | -75.67% | -195.67% |
| Income Tax Expenses | -23,155.21% | -23,510.42% | -49,538.67% | -52,633.56% | 43.86% |
| Earnings from Continuing Operations | 368.03% | 371.43% | -35.26% | -31.07% | -195.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 368.03% | 371.43% | -35.26% | -31.07% | -195.46% |
| EBIT | 421.32% | 425.40% | -75.29% | -73.69% | -160.12% |
| EBITDA | 467.66% | 472.34% | -74.08% | -72.40% | -153.01% |
| EPS Basic | 366.05% | 369.42% | -35.83% | -31.68% | -194.50% |
| Normalized Basic EPS | 347.50% | 350.66% | -77.35% | -75.89% | -194.86% |
| EPS Diluted | 322.69% | 325.51% | -33.62% | -29.34% | -202.26% |
| Normalized Diluted EPS | 315.53% | 318.28% | -77.22% | -75.75% | -196.16% |
| Average Basic Shares Outstanding | 0.74% | 0.74% | 0.89% | 0.89% | 1.03% |
| Average Diluted Shares Outstanding | 15.69% | 15.69% | 0.29% | 0.29% | -0.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
